We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Provisional assignment of new diseases of uncertain etiologySymptoms and signs involving cognition, perception, emotional state and behaviour
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Cognitive impairment is increasingly recognised as a major component of long Covid,and is estimated to be present in 25-75% of affected individuals. This impairment impacts quality of life and the loss of functional ability has major consequences for affected people,their families and the wider economy given people’s difficulty in returning to work.
We propose a two-stage study for investigation and treatment of “cognitive Covid”.
Stage 1 will determine those aspects of cognitive function that are particularly affected in cognitive Covid and the severity of the impairment. We will also explore the relationship between cognitive impairment and other aspects of long Covid,namely fatigue,anxiety,depression and sleep disturbance. MRI scanning will be used to measure brain structure and connectivity,to identify the brain networks affected in cognitive Covid that may underpin the cognitive dysfunction.
Stage 2 will focus on helping people recover from cognitive Covid. This will involve use of rehabilitation strategies aimed at improving function in those cognitive functions identified in Stage 1 as being most affected,and assessing the benefit of rehabilitation on quality of life and people’s ability to return to everyday function. These strategies will be co-produced in collaboration with a group of people living with cognitive Covid. At the end of Stage 2 we will produce a freely available “Covid-19 Cognitive Recovery Guide” for affected people,their close contacts and clinicians.
In conclusion,cognitive impairment is frequently observed in long Covid but at present little is understood about its nature,or how it can be treated. The sheer scale of the CV19 pandemic makes this a top priority unmet need for healthcare worldwide. The aim of this study is to meet this need and to deliver a treatment plan for affected people which will help them return to normal life and working ability.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Type: Psychological & Behavioural;
You can take part if:
You may not be able to take part if:
• Cognitive impairment prior to CV19 infection • Occurrence of acute neurological disorder,such as stroke or encephalitis,that could give rise to cognitive sequelae • People who are on any medications that are considered by the study investigators to have significant adverse effects on cognition • A pre-existing major psychiatric or medical disorder that is considered by the study investigators to have potential to affect cognition • High alcohol intake • Recreational drug use • Loss of mental capacity such that the affected individual is unable to give informed consent • Participants will not be eligible for Workstream 2 if they do not exhibit significant impairment on baseline cognitive assessments,as they will not gain from cognitive rehabilitation.
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
The study is sponsored by University College London and funded by NIHR Central Commissioning Facility (CCF) .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 54973
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
